Ischemia modified albumin: An oxidative stress marker in β-thalassemia major

Clinica Chimica Acta

Volumn 413, Issue 9-10, 2012, Pages 907-910

  Awadallah, Samir M ^a   Atoum, Manar F ^b   Nimer, Nisreen A ^b   Saleh, Suleiman A ^b  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

^b HASHEMITE UNIVERSITY   (Jordan)

Author keywords

Ischemia modified albumin; Oxidative stress; Thalassemia

Indexed keywords

AMINOTRANSFERASE; CERULOPLASMIN; FERRITIN; ISCHEMIA MODIFIED ALBUMIN; MALONALDEHYDE;

ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; THALASSEMIA MAJOR;

ADOLESCENT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; ISCHEMIA; MALE; OXIDATIVE STRESS; SERUM ALBUMIN; YOUNG ADULT;

EID: 84858618285     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.037     Document Type: Article

References (34)

1. Weatherall D.J. Hemoglobinopathies worldwide: present and future. Curr Mol Med 2008, 8:592-599.
2. Olivieri N.F. The beta-thalassemias. N Engl J Med 1999, 341:99-109.
3. Nathan D.G., Gunn R.B. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med 1966, 41:815-830.
4. Koren A., Fink D., Admoni O., Tennenbaum-Rakover Y., Levin C. Non-transferrin bound labile plasma iron and iron overload in sickle cell disease: a comparative study between sickle cell disease and β-thalassemic patients. Eur J Haematol 2010, 84:72-78.
5. Chakraborty D., Bhattacharyya M. Antioxidant defense status of red blood cells of patients with b-thalassemia and E/beta-thalassemia. Clin Chim Acta 2001, 305:123-129.
6. Kassab-Chekir A., Laradi S., Ferchichi S., et al. Oxidant, antioxidant status and metabolic data in patients with beta thalassemia. Clin Chim Acta 2003, 338:79-86.
7. Walter P.B., Fung E.B., Killilea D.W., et al. Oxidative stress and inflammation in iron overloaded patients with β-thalassaemia or sickle cell disease. Br J Haematol 2006, 135:254-263.
8. Livrea M.A., Tesoriere L., Pintaudi A.M., et al. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996, 88:3608-3614.
9. Cabantchik Z.I., Breuer W., Zanninelli G., Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005, 18:277-287.
10. Chan B., Dodsworth N., Woodrow J., Tucker A., Harris R. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995, 227:524-528.
11. Bar-Or D., Curtis G., Rao N., Bampos N., Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. Eur J Biochem 2001, 268:42-47.
12. Bar-Or D., Lau E., Winkler J.V. Novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J Emerg Med 2000, 19:311-315.
13. Roy D., Quiles J., Gaze D.C., Collinson P., Kaski J.C., Baxter G.F. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006, 92:113-114.
14. Sbarouni E., Georgiadou P., Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011, 49:177-184.
15. Kaefer M., Piva S.J., De Carvalho J.A., et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010, 43:450-454.
16. Duarte M.M., Rocha J.B., Moresco R.N., et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009, 42:666-671.
17. Valle Gottlieb M.G., da Cruz I.B., Duarte M.M., et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2010, 95:586-591.
18. Cichota L.C., Moresco R.N., Duarte M.M., da Silva J.E. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008, 22:1-5.
19. Piva S.J., Duarte M.M., Da Cruz I.B., et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem 2011, 44:345-347.
20. Bhagavan N.V., Ha J.S., Park J.H., et al. Utility of serum fatty acid concentrations as a marker for acute myocardial infarction and their potential role in the formation of ischemia-modified albumin: a pilot study. Clin Chem 2009, 55:1588-1590.
21. Borderie D., Allanore Y., Meune C., Devaux J.Y., Ekindjian O.G., Kahan A. High ischemia modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 2004, 50:2190-2193.
22. Schosinsky H., Lehmann H.P., Beeler M.F. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 1974, 20:1556-1563.
23. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 1978, 52:302-310.
24. Awadallah S.M., Nimer N.A., Atoum M.F., Saleh S.A. Association of haptoglobin phenotypes with ceruloplasmin ferroxidase activity in β-thalassemia major. Clin Chim Acta 2011, 412:975-979.
25. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
26. Floris G., Medda R., Padiglia A., Musci G. The physiopathological significance of caeruloplasmin. Biochem Pharmacol 2000, 60:1735-1741.
27. Young S.P., Fahmy M., Golding S. Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells. FEBS Lett 1997, 411:93-96.
28. Attieh Z.K., Mukhopadhyay C.K., Seshadri V., Tripoulas N.A., Fox P.L. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem 1999, 274:1116-1123.
29. Sarkar J., Seshadri V., Tripoulas N.A., Ketterer M.E., Fox P.L. Role of ceruloplasmin in macrophage iron efflux during hypoxia. J Biol Chem 2003, 278:44018-44024.
30. Silva Andre M.N., Hider Robert C. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. Biochim Biophys Acta 2009, 1794:1449-1458.
31. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003, 102:2670-2677.
32. Gutteridge J.M., Rowley D.A., Griffiths E., Halliwel B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic hemochromatosis. Clin Sci 1985, 68:463-467.
33. Naithani R., Chandra J., Bhattacharjee J., Verma P., Narayan S. Peroxidative stress and antioxidant in children with beta thalassemia major. Pediatr Blood Cancer 2006, 46(7):780-785.
34. Scott M.D., Van den Berg J.J.M., Repka T., et al. Effect of excess β-hemoglobin chains on cellular and membrane oxidation in model β-thalassemic erythrocytes. J Clin Invest 1993, 91:1706-1712.